2-amino-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide

• ChemBase编号: 154520
• 分子式: C13H14N4O3S
• 平均质量: 306.34026
• 单一同位素质量: 306.07866133
• SMILES: Cc1c(sc(n1)N)C(=O)N/N=C/c1ccc(c(c1)OC)O
• Canonical SMILES: COc1cc(/C=N/NC(=O)c2sc(nc2C)N)ccc1O
• InChI: InChI=1S/C13H14N4O3S/c1-7-11(21-13(14)16-7)12(19)17-15-6-8-3-4-9(18)10(5-8)20-2/h3-6,18H,1-2H3,(H2,14,16)(H,17,19)
• InChIKey: AMHQGUWEVRTTJB-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-amino-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide
• IUPAC传统名: 2-amino-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide
• 别名: 2-Amino-N′-(4-hydroxy-3-methoxybenzylidene)-4-methyl-1,3-thiazole-5-carbohydrazide; 5-Thiazolecarboxylic acid, 2-amino-4-methyl-, 2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide; OM137

登记号

• CAS号: 292170-13-9
• MDL号: MFCD02086738
• PubChem SID: 162248659
• PubChem CID: 5932799

理论计算性质

• Acid pKa: 9.537589
• 质子受体: 6
• 质子供体: 3
• LogD (pH = 5.5): 1.2781603
• LogD (pH = 7.4): 1.2767098
• Log P: 1.2798246
• 摩尔折射率: 80.4373 cm^3
• 极化性: 29.232449 Å^3
• 极化表面积: 109.83 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO: >10 mg/mL
• 外观: powder

安全信息

• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22-36/37/38
• 安全公开号: 26
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302-H315-H319-H335
• GHS警示性声明: P261-P305 + P351 + P338
• 保存温度: room temp

产品相关信息

• 纯度: ≥95% (NMR)
• Empirical Formula (Hill Notation): C13H14N4O3S

详细说明

Sigma Aldrich - O8140

Biochem/physiol Actions
OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint. OM137 is an aminothiazole derivative, which functions to override the spindle checkpoint primarily through inhibition of the Aurora kinases (mitotic kinases). OM137 is a more potent inhibitor of Aurora B compared with Aurora A in vitro, consistent with the effects of OM137 on checkpoint function in living cells. The compound has some CDK1 inhibitory activity, but is likely that the major mode by which OM137 drives mitotic exit of cells arrested in M phase via the spindle checkpoint is through its inhibitory activity against Aurora B kinase. The compound is less potent than N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride (Sigma Cat. D6068), which is more suited for in vitro testing due to low solubility and high serum binding. OM137 is less potent than selective Aurora A inhibitor, cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide (Sigma Cat. C2368).